Amycretin: A Literature Course on What the Published Studies Report

Amycretin is an investigational peptide that the published literature describes as a unimolecular agonist acting at both the glucagon-like peptide-1 (GLP-1) receptor and the amylin receptor, meaning one peptide sequence rather than two co-administered drugs (PMID 40550229, PMID 40550231). This course page summarises what four peer-reviewed publications did and what researchers reported, module by module, and ends each module with the limits of that evidence.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health or treatment decision. Nothing on this page is a protocol, a schedule, or a recommendation, and the descriptions below are historical accounts of completed research rather than guidance for use.

Course map

Module 1 — What amycretin is and how it has been studied

Definition and class

The published titles of the two 2025 Lancet reports both define amycretin as a GLP-1 and amylin receptor agonist, with one describing it as "first-in-class" (PMID 40550229) and the other describing a subcutaneously administered version (PMID 40550231). In pharmacological terms it belongs to the incretin-based peptide class, but it is distinguished in the literature from single-target GLP-1 receptor agonists because amylin receptor activity is built into the same molecule (PMID 41850421).

Origin and forms studied

A 2026 review in Metabolism placed amycretin within the wider development of combination incretin and amylin pharmacology for obesity, discussing mechanisms, clinical findings to date and future research directions (PMID 41850421). Two administration routes appear in the published record: the phase 1b/2a report specifies subcutaneous administration in its title (PMID 40550231), while the first-in-human phase 1 trial was published as a double-blind, randomised, placebo-controlled study of the same molecule (PMID 40550229).

How it has been studied

The evidence base is small and early. It comprises preclinical work in mice and rats examining body weight and metabolic dysfunction (PMID 40706446), a first-in-human phase 1 trial whose stated objectives were safety, tolerability, pharmacokinetics and pharmacodynamics (PMID 40550229), a randomised controlled phase 1b/2a study of subcutaneous dosing (PMID 40550231), and a narrative review synthesising these findings (PMID 41850421).

Limits of the evidence in Module 1: the definition and class of amycretin rest on a handful of publications from a single development programme. There are no published phase 3 trials, no independent replication of the human findings by unrelated groups, and no long-term human data. Descriptions of "first-in-class" status reflect the ordering of publications, not a statement about comparative effectiveness.

Module 2 — Mechanism as described in the literature

Two receptor systems, one peptide

The 2026 review describes amycretin as engaging two appetite-relevant signalling systems simultaneously: the GLP-1 receptor pathway, which the incretin literature associates with glucose-dependent insulin secretion and reduced food intake, and the amylin receptor pathway, which is associated in that literature with satiation signalling (PMID 41850421). Because both activities reside in one peptide, the review frames amycretin as a co-agonist rather than a combination product (PMID 41850421).

What the animal work examined mechanistically

The 2025 EBioMedicine study examined the effect of amycretin on body weight and on markers of metabolic dysfunction in mice and rats, which allowed researchers to look at food intake and metabolic endpoints in controlled rodent settings rather than inferring mechanism from human weight change alone (PMID 40706446). The review uses such rodent data, together with the early human trials, to argue that the dual-receptor design is the proposed explanation for the metabolic effects observed (PMID 41850421).

Pharmacodynamic measures in humans

The first-in-human phase 1 trial listed pharmacodynamics among its stated objectives, meaning researchers measured biological responses to dosing alongside safety and exposure (PMID 40550229). The phase 1b/2a study then assessed subcutaneous administration in a randomised controlled design (PMID 40550231).

Limits of the evidence in Module 2: mechanism here is largely inferred. The rodent study characterised effects in animals, whose energy metabolism differs from human physiology (PMID 40706446), and the review is a narrative synthesis rather than a systematic analysis of receptor-level data (PMID 41850421). No published human study has isolated the amylin component from the GLP-1 component of the molecule, so the relative contribution of each pathway in people remains untested.

Module 3 — Reported outcomes by study

The table below summarises design and reported direction of findings. It does not restate numerical results, because this page limits itself to what can be attributed directly to the cited publications.

Reading the outcome literature carefully

Two features of this evidence base matter for interpretation. First, the human studies were early-phase: their design priority was safety, tolerability and exposure characterisation rather than definitive efficacy, as the first-in-human title itself states (PMID 40550229). Second, phase 1b/2a studies are typically sized to detect signals and dose relationships, not to establish long-term outcomes, and the published subcutaneous report is described as a randomised controlled study at that stage (PMID 40550231).

Limits of the evidence in Module 3: no published amycretin trial has reported cardiovascular outcomes, mortality, or other event-driven endpoints; no head-to-head randomised comparison against an approved obesity or diabetes medicine appears in the verified literature; and rodent findings (PMID 40706446) cannot be translated into expected human results. Early-phase findings frequently change in larger trials, and the 2026 review explicitly framed further work as a future perspective rather than a settled question (PMID 41850421).

Module 4 — Amycretin Side Effects: What Studies Report

Adverse events in the amycretin literature come from two early-phase human trials, both of which placed safety and tolerability among their primary objectives. The first-in-human phase 1 trial was designed specifically to characterise safety and tolerability alongside pharmacokinetics and pharmacodynamics in a double-blind, randomised, placebo-controlled format, which allowed researchers to compare event frequencies against placebo (PMID 40550229). The phase 1b/2a study of subcutaneous amycretin likewise reported safety outcomes within a randomised controlled design (PMID 40550231).

Class context described in the review

The 2026 Metabolism review discussed tolerability alongside mechanism and clinical efficacy, situating amycretin within the incretin and amylin agonist class in which gastrointestinal effects are the characteristic tolerability issue (PMID 41850421). Readers comparing publications should note that the first-in-human report and the subcutaneous phase 1b/2a report used different administration approaches, so their adverse-event profiles are not interchangeable (PMID 40550229, PMID 40550231).

Why numbers are not restated here

This page does not reproduce event rates or severity gradings. Adverse-event tables in early-phase trials are dose-cohort specific, and quoting a single figure out of its cohort context can misrepresent the record; the primary reports remain the appropriate source for those details (PMID 40550229, PMID 40550231).

Limits of the evidence in Module 4: early-phase trials enrol small, screened populations over short periods, so rare and delayed adverse events would not be expected to appear. Neither published trial was powered as a safety study for long-term use, and no post-marketing surveillance exists because no amycretin product has been approved. The review's tolerability discussion is a synthesis of those same early data rather than new evidence (PMID 41850421).

Module 5 — Pharmacokinetics where data exist

Human pharmacokinetic data for amycretin originate mainly from the first-in-human phase 1 trial, which named pharmacokinetics as an explicit objective and therefore measured drug exposure after dosing in a placebo-controlled setting (PMID 40550229). The phase 1b/2a report addressed subcutaneous administration, a route relevant to exposure characteristics of peptide therapeutics (PMID 40550231). The 2026 review incorporated these pharmacological properties into its overview of the molecule's development (PMID 41850421).

Why route matters in the published record

Peptides differ substantially in absorption and systemic exposure depending on how they are administered, which is why the subcutaneous route is specified in the title of the phase 1b/2a report rather than left implicit (PMID 40550231). Comparisons across amycretin publications therefore need to account for route before any exposure figures are set side by side (PMID 40550229).

Limits of the evidence in Module 5: published pharmacokinetic characterisation is confined to early-phase cohorts. The verified literature contains no dedicated studies of hepatic or renal impairment, drug–drug interactions, use in pregnancy or lactation, paediatric or older-adult pharmacokinetics, or immunogenicity over extended dosing. Any pharmacokinetic parameter quoted elsewhere should be traced to the primary phase 1 report before it is relied upon (PMID 40550229).

Module 6 — Regulatory status, stated factually

Approval status

As of the publications summarised here, amycretin is an investigational compound. No medicine containing amycretin has been approved by the US Food and Drug Administration, the European Medicines Agency, or other major regulators, and the published human studies are phase 1 and phase 1b/2a trials — stages that precede any marketing application (PMID 40550229, PMID 40550231). Approved products exist in the adjacent GLP-1 receptor agonist class, but those approvals apply to specific, separately studied molecules and do not extend to amycretin.

Research-use-only material

Peptides labelled "research use only" (RUO) are sold as laboratory chemicals for in vitro or preclinical work. RUO labelling is not a regulatory approval, carries no assurance of identity, purity, sterility or potency for human administration, and RUO material is not intended for human use. Regulators have repeatedly stated that unapproved peptide products marketed outside the drug-approval framework fall outside quality and safety oversight.

Compounding

In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally requires that a bulk drug substance be the subject of a USP or NF monograph, be a component of an FDA-approved drug, or appear on the applicable FDA bulks list. An investigational peptide with no approved product and no monograph does not meet those criteria. This is a description of the regulatory framework and is not legal advice; questions about a specific jurisdiction or practice setting belong with a qualified attorney or the relevant regulator.

Limits of the evidence in Module 6: regulatory status is a moving target. Approval decisions, bulks lists and enforcement priorities change, and this page reflects a framework rather than a real-time register. The publications cited establish the development stage of the molecule, not its future regulatory outcome (PMID 41850421).

What the studies did not test

Reading the four verified publications together, several categories of question remain entirely open:

• Long-term outcomes. No published amycretin trial assessed cardiovascular events, kidney outcomes, mortality, or durability of any metabolic change after dosing stopped (PMID 40550229, PMID 40550231).
• Comparative effectiveness. The verified literature contains no randomised head-to-head trial against an approved GLP-1 receptor agonist or dual agonist, so ranking claims cannot be sourced to it (PMID 41850421).
• Special populations. Pregnancy, lactation, paediatric use, advanced organ impairment and significant psychiatric or eating-disorder comorbidity were not the subject of the published studies.
• Non-metabolic uses. Reported endpoints in rodents concerned body weight and metabolic dysfunction (PMID 40706446); uses outside that scope have not been tested.
• Non-trial products. Nothing in the literature evaluated material obtained outside a controlled clinical trial, so published findings cannot be transferred to unverified substances.

In short, the amycretin record is an early-stage, mechanism-plus-safety literature: a rodent characterisation study, two early-phase human trials, and a review that frames the remaining questions as future work (PMID 40706446, PMID 41850421). This page is educational and is not medical advice; a licensed physician is the appropriate source for individual medical questions.

References

• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (Lancet, 2025)
• Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (Lancet, 2025)
• The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats (EBioMedicine, 2025)
• Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives (Metabolism: Clinical and Experimental, 2026)